Home » Research » Research Highlights

Research Highlights

Helped develop lifesaving procedures including angioplasty and drug-eluting stents, and newer technologies such as off-pump surgery.
Created lamivudine (3TC) and emtricitabine (FTC), two of the most commonly used and most successful HIV/AIDS drugs, taken by more than 94% of U.S. patients on therapy and by thousands more around the world
Developed one of the leading vaccine candidates against HIV, already tested in preclinical and early stage clinical trials and currently in phase II trials
Developed brain mapping to guide effective surgical approaches (deep brain stimulation) to treat movement disorders such as Parkinson's and dystonia
Discovered the gene responsible for fragile X syndrome, the most common cause of inherited intellectual disability, and now working to develop drug therapy to treat it.
Helped develop belatacept, a post-transplant drug that is less toxic and more effective than current immunosuppressants.
Discovered the role of PD-1 (programmed cell death 1) in inhibiting the T cell immune response to chronic viral infections.
Discovered in the laboratory, then in early-stage clinical trials, the beneficial effects of progesterone to treat traumatic brain injury, the first new treatment for TBI in 30 years. Currently leading a large nationwide NIH-supported clinical trial of progesterone and TBI.
Developing an effective method of using deep-brain stimulation as therapy for treatment-resistant severe depression.

Winship Cancer Institute of Emory University is the only National Cancer Institute-designated cancer center in Georgia.
The Yerkes National Primate Research Center of Emory University is one of only eight NIH-designated national primate research centers in the country.
Emory is one of eight NIH-sponsored Vaccine Evaluation and Treatment Units (VTEUs) conducting clinical trials for vaccines for infectious diseases, including H1N1 flu.
Emory is a leader in technology transfer, with more than 50 products in various stages of development of regulatory approval – 27 products having reached the marketplace and 12 more in human clinical trials. Over the past two decades, the WHSC has helped Emory launch 57 start-up companies and bring more than $806 million into Georgia in licensing revenues from drugs, diagnostics, devices, and consumer products.
The research partnership between Emory and Georgia Tech includes the No. 2-ranked (U.S. News & World Report) Wallace H. Coulter Department of Biomedical Engineering, the Georgia Tech-Emory Center for Regenerative Medicine (GTEC), the Emory/Georgia Tech Predictive Health Institute, and one of the nation's largest NIH-funded research programs in nanomedicine.